**Title:** Gender-specific risk factors for incident sarcopenia: 8 years follow up of the English Longitudinal Study of Aging

**Authors**

Lin Yang1, Lee Smith2, Mark Hamer3

1 Department of Epidemiology, Center for Public Health, Medical University of Vienna, Austria

2 The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge

3 School of Sport, Exercise Health Sciences, Loughborough University, Loughborough, UK

**Corresponding authors:** Lin Yang, Department of Epidemiology, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1st Floor, 1090 Vienna, Austria. Tel: +43(0)1 40160-34705. Email: lin.yang@muv.ac.at

**Abstract**: 248

**Word count**: 1,470

**Key words**: gender, sarcopenia, handgrip strength,

**Conflicts of interest statement**: The authors have no conflicts of interest to declare.

**What is already known on this subject?**

The aetiology of sarcopenia is not well understood, but it is highly prevalent in older adults.

Previous investigations using cross-sectional and retrospective design suggested that physical activity may prevent sarcopenia.

The aging processes differ between men and women.

**What this study adds?**

Women are at 20% higher risk of developing incident sarcopenia than men.

Men benefit from physical activity of moderate and vigorous intensities in preventing incident sarcopenia, but this benefit requires vigorous intensity in women, which might be due to differed hormone production.

Social factors, wealth, appeared to be more strongly preventive of sarcopenia in men, suggesting gender as a social and psychological factor that is not merely biological.

**ABSTRACT**

**Background**: The aetiology of age-related sarcopenia is not known.

**Objectives**: To investigate if risk of developing sarcopenia differs by gender; and to identify gender-specific risk factors of incident sarcopenia, in a large population-based cohort of older English adults.

**Methods**: The sample (n=3,404; age 63.4 (SD 7.7) yrs; 54.1% female) comprised older community dwelling adults recruited from the English Longitudinal Study of Ageing. Sarcopenia was defined as hand grip <26kg in men, <16kg in women. Handgrip strength was assessed at baseline (2004/5) and repeated at follow up (2012/13). Analysed risk factors included baseline anthropometric measures, smoking, vigorous and moderate physical activity, depressive symptoms, chronic illnesses, and wealth. After excluding participants with sarcopenia at baseline, multivariate logistic regressions were used to explore baseline risk factors for incident sarcopenia.

**Results**: During 8 years follow up, 208 and 287 cases of sarcopenia were identified in men (n=1564) and women (n=1840), respectively. Women were at 20% (age adjusted OR=1.20, 95% CI, 0.98, 1.47) higher risk of developing sarcopenia than men. The inverse association between physical activity and sarcopenia risk was observed at moderate (OR=0.44, 95% CI, 0.27, 0.67) and vigorous (0.53, 95% CI, 0.31, 0.82) intensities in men and only vigorous (OR=0.44, 95% CI, 0.28, 0.68) intensity in women. Social factors, such as wealth, and chronic health conditions appeared to be more strongly associated with sarcopenia in men.

**Conclusion**: Women are at higher risk of developing incident sarcopenia than men and this is likely explained by a range of gender-specific risk factors.

**INTRODUCTION**

Age-related sarcopenia is one of the most deleterious effects of aging. Presenting with loss of muscle mass, strength and function, sarcopenia has a major impact on quality of life in the elderly, development of physical disability, and mortality [1, 2]. The aetiology of sarcopenia is not well understood, but it is highly prevalent in older adults; up to 20% of the older population worldwide are thought to be living with sarcopenia, even among the apparently healthy [3]. Coupled with the rapidly growing ageing population worldwide, sarcopenia is projected to result in excessive health care and economic burden in the near future [4].

Several mechanisms have been proposed to explain the development of sarcopenia, centering on protein synthesis, proteolysis, neuromuscular integrity and muscle fat content [5]. Recent epidemiological studies support the role of physical activity as a protective factor against sarcopenia development, yet the basis of current evidence is cross-sectional or retrospective investigations [6]. Moreover, only few investigations [7] have considered gender-specific risk factors in sarcopenia, despite the clear difference in immune response homeostasis between men and women and subsequent disease risks in their aging process [8].

To fill the knowledge gap, primary aims of the present study were to investigate 1) if risk of prospectively developing sarcopenia differs by gender; and to identify 2) gender-specific risk factors of incident sarcopenia, in a large population based cohort of older English adults.

**METHODS**

The English Longitudinal Study of Ageing (ELSA) is a cohort study of older, community dwelling adults previously described [9]. Data on grip strength was first collected at wave 2 (2004/5), and was thus used as the baseline for the present analyses. Handgrip assessments were repeated at wave 6 (2012/13) in survivors. Participants gave full informed consent to participate in the study. Ethical approval was obtained from the London Multi-center Research Ethics Committee, compliant with the Declaration of Helsinki. Anthropometric data (waist, hip), and grip strength were collected by trained nurses. Participants were excluded from hand grip tests if they had swelling or inflammation, severe pain, or a recent injury or surgery to the hand in the preceding 6 months. Handgrip strength (kg) of the dominant hand was assessed using the Smedley hand-held dynamometer (Stoelting Co, IL, USA), using the average of three measurements from the dominant hand. Participants held the device at a right angle to their body and exerted maximum force for a couple of seconds when instructed. Waist circumference was recorded twice midway between the iliac crest and lower rib and hip circumference around the widest portion of the buttocks using measuring tape. Central obesity was defined using waist to hip ratio (WHR) World Health Organization criteria (WHR≥0.85 in women and WHR≥0.90 in men) [10]. Trained interviewers asked questions on cigarette smoking (current, ex-smoker or non-smoker), alcohol consumption (1-4/week, rarely, not in past 12 months), frequency of vigorous, moderate- and low-intensity physical activity (> once a week, once a week, 1 – 3 times a month, and hardly ever/never), depressive symptoms (using a score >3 on the 8-item Centre of Epidemiological Studies Depression scale), activity limiting illness (no, yes)[11] and diabetes (no, yes). Wealth was grouped into quintiles, comprising of the total value of the participant’s home (excluding mortgage), and other financial assets. Sarcopenia was defined as hand grip <26kg men, <16kg women [12]. After excluding participants with sarcopenia at baseline we used multivariate logistic regression to explore longitudinal associations between psychosocial and clinical risk factors with incident sarcopenia. All analyses were conducted using SPSS version 22 (SPSS, Chicago, IL).

**RESULTS**

At baseline 7,666 participants provided data on handgrip strength. After removing participants with sarcopenia at baseline (n=1,265), those that died through follow up (n=796), and those with missing covariates and follow-up data (n= 2,201) the analytic sample for multivariate logistic regression analyses comprised 3,404 participants (mean age 63.4 (SD 7.7) yrs; 54.1% female). During 8 years follow up, 208 and 287 cases of sarcopenia were identified in men (n=1564) and women (n=1840), respectively.

We observed an elevated risk of developing sarcopenia among women (OR=1.20, 95% CI, 0.98, 1.47) comparing to men in the age-adjusted model. In multivariate adjusted gender-specific models, age and physical activity level were significantly associated with incident sarcopenia in both genders. Such that older age were associated with higher risk of sarcopenia (men, OR=1.16, 95% CI, 1.14, 1.19; women, OR=1.12, 95% CI, 1.10, 1.14); physical activity of moderate (OR=0.44, 95% CI, 0.27, 0.67) and vigorous (0.53, 95% CI, 0.31, 0.82) intensities were protective of sarcopenia in men, but an association was only exhibited at vigorous intensity (OR=0.44, 95% CI, 0.28, 0.68) in women.

Activity limiting illness was associated with higher risk of developing sarcopenia in men (OR=1.49, 95% CI, 1.03, 2.18) but not in women (OR=1.29, 95% CI, 0.94, 1.77). Similarly, baseline diabetes diagnosis was associated with higher likelihood of incident sarcopenia in men (OR=2.43, 95% CI, 1.50, 3.95) but not in women (OR=1.49, 95% CI, 0.83, 2.68). Higher wealth status was associated with lower risk of sarcopenia in a dose-response manner, particularly in men. We observed no statistically significant associations in relation to incident sarcopenia with other risk factors, including smoking, alcohol consumption, depressive symptoms, and central obesity (Table 1).

**DISCUSSION**

In the present population based sample of older English adults, women were at 20% higher risk of developing sarcopenia than men over 8 years follow-up. There appear to be a range of gender-specific risk factors for incident sarcopenia, notably, the benefit of physical activity at moderate and vigorous intensities in men and only vigorous intensity in women. In addition, social factors, such as wealth, appeared to be more strongly preventive of sarcopenia in men. Chronic conditions such as activity limiting illness and diabetes may put men at higher risk of incident sarcopenia, likely owing to low levels of physical activity associated with such conditions.

Our findings support previous research on the role of physical activity in preventing sarcopenia [6]. The present study is one of the first to extend the beneficial influence of physical activity with longitudinal data. The greater benefit of physical activity engagement in men than in women has been previously reported in a cross-sectional study [13] that found associations of physical activity with muscle volume and functional parameters in men, but null association in women. In that study, physical activity was defined using average MET (metabolic equivalent) value. This approach does not consider the intensity of physical activity, unlike the present approach that identified the benefit of vigorous physical activity in women. The stronger association of physical activity with incident sarcopenia in men than in women could also explain the higher risk of incident sarcopenia in men with activity limiting illness and diabetes but not in women, since such conditions often restrict individuals from being physically active.

There is a growing interest in gender-specific differences in the development of sarcopenia, notably the role of androgens given that mechanistic studies found testosterone levels to be associated with sarcopenia [14]. Moreover, recent *in vivo* and *in vitro* studies suggested that testosterone may enhance the benefit of low-intensity physical training on skeletal muscle mitochondrial function in elderly male mice [15]. Owing to different male and female homeostasis, it is likely that male muscle anabolic activity is more prone to external stimuli (such as physical activity) than women [16].

Another protective factor of incident sarcopenia identified in men was a higher level of wealth. This finding is important because ageing is a complex process and not merely biological. Wealth is a key indicator of socioeconomic status in this population. We speculate that level of wealth may signify the quality of nutrition, yet it is unclear why the impact of wealth on incident sarcopenia differs between men and women. Future research should consider the inclusion of gender as a social and psychological factor to identify how social economics and contextual factors may later influence the risk of sarcopenia.

Strengths of the present study include the large population based sample of older English adults and the longitudinal design. However, the data must be interpreted considering the following limitations. We used a single measure of muscle strength to assess sarcopenia. Although a unified geriatric assessment tool is yet to be widely implemented to diagnose sarcopenia, handgrip strength has been commonly used to measure muscle strength, a critical component of sarcopenia [5]. It has been widely used in research and clinical settings [17, 18] and shown to be an independent predictor of all-cause mortality [19, 20]. Other limitations include limited adjustment for sub-clinical disease process and severity of disease. Further, participants retained in our analyses were generally healthier than the overall sample, thus bias may rise with likely lower incidental sarcopenia in the analysed sample.

In conclusion, the present longitudinal analyses suggest that women are at 20% higher risk of developing incident sarcopenia than men that may be explained by a range of gender-specific risk factors.

**REFERENCES**

1 Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. *Journal of cachexia, sarcopenia and muscle* 2016;**7**:290-8.

2 Guralnik JM, Ferrucci L, Pieper CF*, et al.* Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. *The journals of gerontology Series A, Biological sciences and medical sciences* 2000;**55**:M221-31.

3 Shafiee G, Keshtkar A, Soltani A*, et al.* Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. *Journal of diabetes and metabolic disorders* 2017;**16**:21.

4 Beaudart C, Rizzoli R, Bruyere O*, et al.* Sarcopenia: burden and challenges for public health. *Archives of public health = Archives belges de sante publique* 2014;**72**:45.

5 Cruz-Jentoft AJ, Baeyens JP, Bauer JM*, et al.* Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age and ageing* 2010;**39**:412-23.

6 Steffl M, Bohannon RW, Sontakova L*, et al.* Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. *Clinical interventions in aging* 2017;**12**:835-45.

7 Tay L, Ding YY, Leung BP*, et al.* Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults. *Age (Dordrecht, Netherlands)* 2015;**37**:121.

8 Berghella AM, Contasta I, Marulli G*, et al.* Ageing gender-specific "Biomarkers of Homeostasis", to protect ourselves against the diseases of the old age. *Immunity & ageing : I & A* 2014;**11**:3.

9 Steptoe A, Breeze E, Banks J*, et al.* Cohort profile: the English longitudinal study of ageing. *International journal of epidemiology* 2013;**42**:1640-8.

10 World Health Organization. Waist circumference and waist–hip ratio Report of a WHO expert consultation. 2011.

11 Hamer M, Lavoie KL, Bacon SL. Taking up physical activity in later life and healthy ageing: the English longitudinal study of ageing. *British journal of sports medicine* 2014;**48**:239-43.

12 Studenski SA, Peters KW, Alley DE*, et al.* The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *The journals of gerontology Series A, Biological sciences and medical sciences* 2014;**69**:547-58.

13 Rivera JJ, Fonseca-Sanchez MA, Rodriguez P*, et al.* Physical Activity Protects Men but Not Women for Sarcopenia Development. *Gerontology & geriatric medicine* 2016;**2**:2333721416667879.

14 Basualto-Alarcon C, Varela D, Duran J*, et al.* Sarcopenia and Androgens: A Link between Pathology and Treatment. *Frontiers in endocrinology* 2014;**5**:217.

15 Guo W, Wong S, Li M*, et al.* Testosterone plus low-intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice. *PloS one* 2012;**7**:e51180.

16 Bilodeau PA, Coyne ES, Wing SS. The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation. *American journal of physiology Cell physiology* 2016;**311**:C392-403.

17 Roberts HC, Denison HJ, Martin HJ*, et al.* A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age and ageing* 2011;**40**:423-9.

18 Veronese N, Stubbs B, Fontana L*, et al.* A Comparison of Objective Physical Performance Tests and Future Mortality in the Elderly People. *The journals of gerontology Series A, Biological sciences and medical sciences* 2017;**72**:362-8.

19 Wu Y, Wang W, Liu T*, et al.* Association of Grip Strength With Risk of All-Cause Mortality, Cardiovascular Diseases, and Cancer in Community-Dwelling Populations: A Meta-analysis of Prospective Cohort Studies. *Journal of the American Medical Directors Association* 2017;**18**:551.e17-.e35.

20 Garcia-Hermoso A, Cavero-Redondo I, Ramirez-Velez R*, et al.* Muscular Strength as a Predictor of All-Cause Mortality in an Apparently Healthy Population: A Systematic Review and Meta-Analysis of Data From Approximately 2 Million Men and Women. *Archives of physical medicine and rehabilitation* 2018.

**Table 1. Risk factors for incident sarcopenia† over 8 years follow up in men and women from ELSA**

|  |  |  |
| --- | --- | --- |
| Baseline risk factor | MenOR (95% CI)[cases=208; n=1564] | WomenOR (95 % CI)[cases=287; n=1840] |
| Age  | 1.16 (1.14, 1.19) | 1.12 (1.10, 1.14) |
| *Physical activity* InactiveModerateVigorous  | 1.0 (Ref)0.44 (0.27, 0.67)0.53 (0.31, 0.82) | 1.0 (Ref)0.85 (0.55, 1.22)0.44 (0.28, 0.68) |
| *Smoking*NoneCurrent  | 1.0 (Ref)1.29 (0.75, 2.19) | 1.0 (Ref)0.80 (0.53, 1.21) |
| *Alcohol*Daily1 – 4 /wkRarelyNot in past 12 months | 1.0 (Ref)1.17 (0.77, 1.76)1.15 (0.75, 1.92)1.02 (0.57, 2.22) | 1.0 (Ref)1.13 (0.74, 1.73)1.13 (0.74, 1.73)1.30 (0.77, 2.22) |
| *Wealth*1 (lowest)2345 (highest) | 1.0 (Ref)0.75 (0.43, 1.38)0.63 (0.35, 1.14)0.52 (0.28, 0.93)0.44 (0.24, 0.81) | 1.0 (Ref)1.26 (0.79, 2.01)0.60 (0.37, 0.95)0.77 (0.47, 1.23)0.63 (0.38, 1.02) |
| *Depressive symptoms*CESD < 4CESD ≥ 4 | 1.0 (Ref)0.82 (0.45, 1.51) | 1.0 (Ref)1.19 (0.81, 1.75) |
| *Activity limiting illness*NoYes  | 1.0 (Ref)1.49 (1.03, 2.18) | 1.0 (Ref)1.29 (0.94, 1.77) |
| *Central obesity*NoYes  | 1.0 (Ref)0.84 (0.60, 1.18) | 1.0 (Ref)1.12 (0.84, 1.49) |
| *Diabetes*NoYes  | 1.0 (Ref)2.43 (1.50, 3.95) | 1.0 (Ref)1.49 (0.83, 2.68) |

†Cases of sarcopenia at follow up defined as hand grip <26kg men, <16kg women;

Participants with sarcopenia at baseline were removed.

Odds ratios are mutually adjusted for all presented variables.